ALT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important October 6 Deadline in Securities Class Action – ALT

Key Takeaways:

• The legal action covers Altimmune securities bought from August 10, 2023, to June 25, 2025.
• A lead plaintiff deadline falls on October 6, 2025.
• Rosen Law Firm, a global investor rights firm, is spearheading this class action.
• Investors may qualify for compensation without out-of-pocket costs.
• A lawsuit is already filed, urging timely investor action.

Overview of the Lawsuit

Altimmune, Inc. (NASDAQ: ALT) is the focus of a securities class action lawsuit now moving forward in federal court. Rosen Law Firm, a global investor rights law firm, has reminded those who purchased Altimmune securities between August 10, 2023, and June 25, 2025, that the window for potential legal recourse will soon close.

Critical Dates and Plaintiff Role

Investors who wish to serve as lead plaintiff must move the Court by October 6, 2025. This date represents the pivotal deadline for individuals who believe they were affected by events during the specified class period. According to the notice, the lead plaintiff “is a representative party acting on behalf of other class members in directing the litigation,” giving them a chance to influence the direction of the lawsuit.

Rosen Law Firm’s Call to Action

Noting its track record in investor rights, Rosen Law Firm encourages investors to come forward. “Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition,” the firm states in its reminder. The law firm also emphasizes that those investors who purchased shares in the identified period “may be entitled to compensation without payment of any out-of-pocket fees or costs” thanks to a contingency arrangement.

Who May Be Affected

Any shareholder who bought Altimmune stock from August 10, 2023, through June 25, 2025, is in the defined class period. Rosen Law Firm’s release stresses that a class action lawsuit against Altimmune has already been filed, making it crucial for anyone with a stake in the company during that timeframe to evaluate their legal options.

Next Steps for Investors

With the deadline fast approaching, investors are encouraged to seek more information regarding their potential claims. Those who fail to act by October 6, 2025, risk losing the chance to serve as lead plaintiff or obtain due compensation.

As the legal proceedings advance, Altimmune shareholders who qualify are urged to consider their eligibility given that “a class action lawsuit has already been filed.” This provides an avenue for possible recovery but also underscores the importance of prompt decision-making.